Maat Pharma, its MaaT033 treatment induces good colonization of the microbiota

Maat Pharma is carried away by the fall in the market on Monday. The title of biotech, recently listed on the stock market, fell 0.8% to 12.40 euros, despite the announcement of promising results. Patients eligible for bone marrow transplantation and treated with its second product in clinical development, MaaT033, showed “ satisfactory safety and good colonization, characterized by the presence of microbial operational taxonomic units in the intestine resulting from the administration of the product and which were not present at the start of the treatment “, indicates the company in a press release. The trial, dubbed Cimon, involved 21 patients from four cohorts. ” These are the first data confirming the mechanism of action of MaaT033 in humans “, welcomes the analyst from the Portzamparc cabinet.

Sufficient data

MaaT033 is intended to improve the survival of patients receiving allogeneic hematopoietic stem cell transplantation (allo-GCSH), which represents approximately 22,000 patients per year in the seven main biotech markets. Its oral formulation must allow targeted delivery in the intestine. Initially, the Cimon study was to include five cohorts of patients, but the biotech believes that the data obtained to date are sufficient. As a result, it decided to close the Cimon phase 1b trial, in order to accelerate the transition to phase 2/3. It could start in the second half of 2022.